NPC(SH:600713)2015-10-29 16:00Financial Performance - Operating revenue for the first nine months reached CNY 18.38 billion, an increase of 11.76% year-on-year[8] - Net profit attributable to shareholders increased by 138.16% to CNY 121.52 million for the first nine months[8] - Basic and diluted earnings per share rose by 82.43% to CNY 0.135[9] - Net profit for the period increased by 128.19% year-on-year, amounting to ¥153,784,280.99, driven by a focus on core business and improved cost control[20] - The company reported a net profit of ¥225,724,406.81 for the period, compared to ¥104,208,502.16 in the previous year, reflecting a significant increase[43] - The total profit for Q3 2015 was negative CNY 11,182,657.00, compared to a loss of CNY 5,173,154.05 in the same quarter last year[55] - The company reported a net profit of CNY 78,222,655.41 for the first nine months, down from CNY 104,564,884.51 in the previous year[55] Cash Flow - Net cash flow from operating activities showed a significant decline of 916.85%, resulting in a negative cash flow of CNY -393.72 million[8] - The net cash flow from operating activities decreased significantly by 916.85% to approximately -¥393.72 million, influenced by industry policy impacts and an increase in accounts receivable[22] - The cash flow from investing activities showed a net outflow of CNY 76,965,978.63, compared to a minor outflow of CNY 502,418.56 in the same period last year[57] - The cash flow from financing activities resulted in a net inflow of CNY 416,591,067.01, contrasting with a net outflow of CNY 382,402,754.45 in the previous year[57] - Operating cash inflow totaled $603.26 million, a decrease of 13.6% compared to $698.30 million in the same period last year[60] - Net cash flow from operating activities was -$143.98 million, contrasting with a positive $119.33 million in the previous year[60] - Cash inflow from financing activities amounted to $4.24 billion, significantly higher than $1.83 billion in the previous year[61] Assets and Liabilities - Total assets increased by 16.29% to CNY 13.21 billion compared to the end of the previous year[8] - The company's cash and cash equivalents decreased by 36.08% from the beginning of the year, totaling ¥1,219,288,020.30[17] - Accounts receivable increased by 34.14% compared to the beginning of the year, reaching ¥6,757,480,218.71, attributed to sales growth and extended aging of receivables due to medical reform policies[17] - Total liabilities increased to ¥10,601,806,402.80 from ¥8,924,967,227.26, representing a rise of 18.8%[43] - Current liabilities totaled ¥10,352,738,375.39, up 19.3% from ¥8,676,221,783.80 at the start of the year[43] - The company's total current assets reached approximately 11.94 billion RMB, an increase from 10.10 billion RMB at the beginning of the year[41] Shareholder Information - The total number of shareholders reached 92,287 at the end of the reporting period[14] - The largest shareholder, Nanjing Pharmaceutical Group, holds 26.94% of the shares[14] - The controlling shareholder committed to not harm the company's independence in operations, assets, and finances[34] - The company plans to avoid any direct or indirect competition with its controlling shareholders in business activities[34] Investment and Financing Activities - The company approved an investment increase of approximately ¥93.20 million for the Nanjing Pharmaceutical Hefei Logistics Center project, expanding the building area by about 20,865 square meters[24] - The company agreed to transfer 28.57% of its stake in Beijing Zhibo Gaoke Biotechnology Co., Ltd. for approximately ¥256.25 million, with ongoing legal proceedings regarding the transaction[26] - The company received a registration notice for short-term financing bonds amounting to 900 million RMB, valid for two years from the date of notification[31] - Cash received from bond issuance was $2.79 billion, compared to $500 million in the previous year[61] Operational Efficiency - The weighted average return on equity increased by 0.532 percentage points to 5.514%[8] - The company's retained earnings increased by 116.61% from the beginning of the year, reaching ¥225,724,406.81, reflecting improved operational performance[18] - The company incurred financial expenses of CNY 59,302,228.07 in Q3 2015, a decrease of 32.2% from CNY 87,398,641.31 in Q3 2014[49] - The total operating costs for the first nine months of 2015 were CNY 18,165,705,239.74, an increase of 10.9% from CNY 16,377,187,421.06 in the previous year[49]